expert highlights: targeting her2 and egfr in nsclc | tejas patil
Published 4 years ago • 263 plays • Length 10:30Download video MP4
Download video MP3
Similar videos
-
9:57
expert highlights: targeted therapy for alk-, ret- and met-driven nsclc | tejas patil
-
3:26
developments in immunotherapy & targeted treatment for mnsclc | tejas patil, md | esmo22 colorado
-
2:54
wclc 2023 highlights: flaura2 and egfr exon20-targeting tkis
-
41:23
multimodal management of early-stage nsclc: egfr-targeted therapy in perioperative settings
-
3:41
lung cancer treatment: how do targeted therapies work?
-
2:14
advanced imaging for precision treatments
-
41:59
testing for common and uncommon egfr mutations to guide egfr-targeted therapy in nsclc
-
43:35
maximizing the impact of egfr-targeted therapy in resectable nsclc
-
1:00:53
drs. sepesi & cascone discuss egfr-targeted therapy in early-stage nsclc: https://bit.ly/3ozllfo
-
12:23
clinical clips: spotlighting hot topics in nsclc harboring egfr mutations
-
0:47
what egfr/her2 vaccine targets
-
1:02:05
adjuvant egfr-targeted therapy as a game changer in multimodal nsclc management
-
4:37
targeted therapy in lung cancer: the importance of biomarkers - lcvl 2024
-
2:40
lung cancer and coronavirus: what patients should know
-
53:02
landscape of lung cancer management in 2020
-
2:07
subtypes of egfr- and her2-mutant metastatic nsclc influence response to icis
-
24:43
egfr / her2 vaccine q&a | march 2023
-
5:00
case 2: testing for egfr in lung adenocarcinoma